A novel brain-computer interface designed to aid recovery in chronic stroke patients has received a breakthrough device designation from the US Food and Drug Administration. The designation is intended to expedite the development and review of the implantable system, which represents a new approach to treating long-term motor impairments.
The system, called Brain Interchange, is developed by the German company CorTec. It is the first BCI to receive this FDA designation specifically for stroke rehabilitation. The device combines two functions: it records brain signals and then delivers adaptive electrical stimulation to the brain in a closed-loop configuration. This means the therapy is continuously adjusted based on the patient's own neural activity, with the goal of supporting motor recovery.
The technology is currently being evaluated in an early clinical trial at the University of Washington. Since the study's approval in May 2024, two patients have been successfully implanted with the device. Company officials note that published long-term data has shown the system can maintain signal stability for over 500 days. Beyond stroke, the platform is also being investigated for potential use in epilepsy, with future plans to explore applications for paralysis and depression.
The global market for neurology devices is projected to grow significantly, exceeding $25 billion by 2034, with brain-computer interfaces like this one nearing commercialization. Analysts anticipate initial market launches for various BCI technologies around the year 2030.
With the breakthrough designation in place, CorTec plans to advance toward larger clinical trials. The company views the FDA decision as providing strong momentum to accelerate its regulatory pathway and move closer to offering a new option for the many patients living with chronic stroke-related disabilities.